Empagliflozin

Manufacturer supply top purity Empagliflozin 864070-44-0 with ISO standards We provide high quality Empagliflozin (CAS 864070-44-0), at a very affordable prices to our customers.

1.What is the Empagliflozin ?

Empagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor, was originally discovered by Boehringer Ingelheim and codeveloped and co-marketed through research collaboration with Eli Lilly and Co. It was first approved by European Medicine Agency (EMA) in May 2014, followed by the approval of the US FDA in August 2014. SGLT2 inhibitors are anewclass of glucose-lowering agents developed for the treatment of type 2 diabetes mellitus, which have a mechanism of action that is independent of pancreatic b-cell function or the degree of insulin resistance. Consequently, SGLT2 inhibitors have the potential to be of use not only as standalone therapy but also in combination with any of the existing classes of glucose-lowering agents, including insulin. Empagliflozin selectively inhibits SGLT2, which in turn prevents glucose reabsorption by excreting excess glucose in the urine.

Empagliflozin is a novel, potent and selective SGLT-2 inhibitor, improves glycaemic control and features of metabolic syndrome in diabetic rats.

2.What is the CAS number for Empagliflozin ?

The CAS number of Empagliflozin is 864070-44-0.

More information of Empagliflozin 864070-44-0 are:

3.What is the molecular formula of Empagliflozin ?

The chemical formula of Empagliflozin is C23H27ClO7 which containing 23 Carbon atoms,27 Hydrogen atoms,1 Chlorine atoms and 7 Oxygen atoms,and the molecular weight, and the molecular weight of Empagliflozin is 450.916

4.What is Empagliflozin(864070-44-0)used for?

Empagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor, was originally discovered by Boehringer Ingelheim and codeveloped and co-marketed through research collaboration with Eli Lilly and Co. It was first approved by European Medicine Agency (EMA) in May 2014, followed by the approval of the US FDA in August 2014. SGLT2 inhibitors are anewclass of glucose-lowering agents developed for the treatment of type 2 diabetes mellitus, which have a mechanism of action that is independent of pancreatic b-cell function or the degree of insulin resistance. Consequently, SGLT2 inhibitors have the potential to be of use not only as standalone therapy but also in combination with any of the existing classes of glucose-lowering agents, including insulin. Empagliflozin selectively inhibits SGLT2, which in turn prevents glucose reabsorption by excreting excess glucose in the urine.

Relevant articles related to Empagliflozin:

5.Manufacturer supply top purity Empagliflozin 864070-44-0 with ISO standards

weifang yangxu group co.,ltd is a quality supplier of Empagliflozin. Our main goal is customer satisfaction. Contact us to negotiate the best price for your business on Empagliflozin 864070-44-0.